# KAHR Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kahr-medical

- Industry: Biotechnology
- Headquarters: Makabim-Re'ut, Israel
- Website: https://kahrbio.com
- Total disclosed funding: $12M
- Latest round: Series C (Sep 10, 2025)
- Investors on record: 5

## About

Founded in 2005 and based in Makabim-Re'ut, Israel, KAHR Medical Ltd. specializes in developing innovative fusion proteins aimed at enhancing cancer therapy by improving immune responses against tumors.KAHR Medical Ltd. focuses on creating solutions for cancer treatment through its proprietary multifunctional fusion proteins. Founded in 2005 in Makabim-Re'ut, Israel, the firm has successfully raised a total of USD 46.50 mn through various funding rounds, with the latest funding round occurring in November 2022 when it raised USD 46.50 mn led by aMoon, alongside other investors such as BVF Partners and Cancer Focus Fund. The company's CEO is Yaron Pereg, who has a history of involvement in the biopharmaceutical sector.KAHR Medical Ltd. addresses the challenges of cancer therapy by providing multifunctional fusion proteins that enhance immune system responses against tumors. These products facilitate the detection and destruction of cancerous cells, particularly in oncology applications. KAHR’s offerings are utilized by pharmaceutical companies, research institutions, and healthcare providers primarily in North America and Europe, serving a diverse clientele including academic researchers and clinical practitioners.KAHR Medical Ltd. generates revenue through strategic partnerships and sales to healthcare institutions and pharmaceutical companies. This includes collaborative research agreements, licensing deals for their technologies, and direct sales of their products. Their revenue model likely features B2B transactions emphasizing long-term client relationships, with tiered pricing structures based on product volume and partnership scale.In November 2022, KAHR Medical Ltd. secured funding to advance the development of DSP107, its leading immunotherapy drug candidate targeted at treating multiple myeloma. The company aims to expand its product portfolio and geographic reach, focusing on new markets that may include Asia and other regions by the end of 2024. This funding will be pivotal in supporting these initiatives and enhancing their presence in the oncology market.

## Funding rounds

- Series C, Sep 10, 2025 — Peregrine Ventures
- Series C, May 1, 2025 — Peregrine Ventures
- Series C, Apr 1, 2024 — Peregrine Ventures
- Series B, Jan 4, 2023 — Peregrine Ventures
- Series B, Dec 15, 2015, $12M — Korea Investment Partners, DSC Investment, Mirae Asset Venture Investment, Flerie Invest

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Flerie Invest (https://capitalatlas.ai/funds/flerie-invest) — Series B
- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series B, Series C